Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS

OBJECTIVE: This phase I study investigated pharmacokinetic (PK) and pharmacodynamic (PD) profiles of natalizumab in pediatric patients with relapsing-remitting MS (RRMS). METHODS: Pediatric patients with RRMS who were prescribed natalizumab 300 mg IV every 4 weeks were enrolled. Blood samples were c...

Full description

Saved in:
Bibliographic Details
Published in:Neurol Neuroimmunol Neuroinflamm
Main Authors: Ghezzi, Angelo, Comi, Giancarlo, Grimaldi, Luigi Maria, Moiola, Lucia, Pozzilli, Carlo, Fantaccini, Simone, Gallo, Paolo
Format: Artigo
Language:Inglês
Published: Lippincott Williams & Wilkins 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624146/
https://ncbi.nlm.nih.gov/pubmed/31355324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000591
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items